Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Key facts
- Who runs it
- Istanbul University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 44 people enrolled
- Started
- 1 Jun 2023
- Ended
- 15 Feb 2026
- Type of study
- Observational, 3 groups
- Record updated
- 13 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Having a diagnosis of primary membranous nephropathy (patient group)
- Having a diagnosis of primary IgA nephropathy (diseased control group)
- Being healthy (healthy control group)
- Agreeing to participate in the research (informed consent)
Who cannot take part
- Refusing to participate in the research
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary membranous nephropathy (MN). A search for disease-related circulating antibodies [anti-phospholipase A2 receptor antibody (anti-PLA2R) and anti-thrombospondin type 1 domain-containing 7A antibody (anti-THSD7A)] in patients' sera is also planned.
Read full original descriptionShow less
The main questions to answer are:
1. What is the relationship of these cell populations and their distribution during follow-up with treatment, treatment responses, and relapses? 2. What is the relationship of the cell populations with anti-PLA2R (or anti-THSD7A) antibody levels?
Participants will provide peripheral venous blood samples at pre-designated regular intervals.
The research team will compare results of the primary MN group with two control groups (IgA nephropathy and healthy volunteer groups) to see if the findings are specific for primary MN.
The 3 groups in the trial
- Study Group (Primary Membranous Nephropathy)
Patients with biopsy-proven primary membranous nephropathy will be included (n=18). Samples will be collected from patients diagnosed with primary MN before starting conventional immunosuppressive therapy with calcineurin inhibitors (CNI) and corticosteroids (CS) and at 3, 6, 12, 18 and 24 months after starting the treatment. In case of failure after treatment with CNIs and CS treatment, rituximab (RTX) is used. If patient switches to RTX, samples will be taken before and 1, 3, 6, 12, 18, and 24 months after the first dose of RTX. If relapse occurs, sampling will be done regardless of the timing. Treatment decisions will solely be made in line with the guidelines, and there will be no intervention.
- Control Group 1 (IgA Nephropathy)
After the patient group sampling is completed, a diseased control group will be formed from patients with primary IgA nephropathy according to the distribution of age and sex (n=12). Samples will be collected from the patients for one time only (cross-sectional sampling).
- Control Group 2 (Healthy Volunteers)
After the patient group sampling is completed, a healthy control group will be formed from healthy volunteers according to the distribution of age and sex (n=14). Samples will be collected from healthy volunteers for one time only (cross-sectional sampling).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Analysis of T- and B-Cell Subpopulations in Patients With Primary Membranous Nephropathy
- Record updated
- 13 July 2026